LONDON--Pharmaceutical company Midatech Pharma PLC (MTPH.LN) said Wednesday that it has signed a global licensing agreement with Novartis AG (NOVN.EB) for the oncology compound panobinostat.

The company intends to develop panobinostat for the treatment of brain tumor.

Shares at 0741 GMT trading 4.4% higher at 108 pence.

Write to Tapan Panchal at tapan.panchal@wsj.com

(END) Dow Jones Newswires

June 07, 2017 03:59 ET (07:59 GMT)

Copyright (c) 2017 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Novartis Charts.
Novartis (NYSE:NVS)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Novartis Charts.